U.S. IT Stock News

Next Technology Holding (NasdaqCM:NXTT) opened 2026 with Q1 revenue of about US$0.5 million and a basic EPS loss of US$1.39 per share, alongside a net loss of US$105.9 million. Over recent quarters the company has seen revenue move from US$0 in Q1 2025 to US$9.8 million in Q4 2025 before landing at US$0.5 million in Q1 2026. EPS has swung from a very high profit of US$396.38 per share in Q1 2025 to a loss of US$1.39 in the latest quarter, setting a backdrop where reported margins look highly...

Wondering whether Blackbaud at around US$37.54 is a bargain or a value trap? This breakdown will help you size up what the current share price really reflects. The stock has been broadly flat over the last month at around 0.0%. However, that sits against a much tougher backdrop with a 36.9% decline year to date and a 38.9% decline over the past year. Those longer term returns mean many holders are sitting on losses, which often pushes valuation questions to the front of investors' minds...

Pro-Dex (PDEX) has put up a solid Q3 2026 print, with revenue of about US$19.9 million and basic EPS of roughly US$1.23, against a trailing twelve month backdrop where earnings grew 28.1% year over year and net profit margin sat at 16.1%. Over recent quarters the company has seen revenue move from around US$17.4 million in Q3 2025 to US$19.9 million in Q3 2026, while quarterly basic EPS ranged between roughly US$0.37 and US$1.43 over that stretch, giving a clear view of how revenue and per...

Jade Biosciences (NasdaqCM: JBIO) appointed Edward R. Conner, M.D. as Chief Medical Officer. The company elevated Andrew King, M.D., Ph.D. to President, Research & Development. These leadership changes focus on clinical development, regulatory strategy, and R&D continuity for Jade's autoimmune pipeline. Jade Biosciences, listed on NasdaqCM under the ticker JBIO, is focused on developing therapies for autoimmune conditions, an area that continues to attract capital and partnerships across...

Wondering if American Healthcare REIT is reasonably priced at around US$50 a share, or if the market is getting ahead of itself? This article walks through what the current numbers actually say about value. The stock recently closed at US$50.15, with returns of 0.1% over 7 days, 5.5% over 30 days, 6.2% year to date and 57.7% over the past year. This naturally raises questions about how much of the story is already reflected in the price. Recent coverage has focused on American Healthcare...

Structure Therapeutics (NasdaqGM:GPCR) plans multiple presentations at the 86th American Diabetes Association Scientific Sessions. The company will share new safety, efficacy, and dosing data for its oral GLP-1 receptor agonist aleniglipron. Additional data will cover a novel amylin receptor agonist combination, including findings on weight loss effects. The presentations focus on combination approaches in obesity and diabetes treatment development. Structure Therapeutics focuses on oral...

Clorox, NYSE:CLX, has completed its acquisition of GOJO Industries, the owner of the Purell brand. The deal adds a broad health and hygiene portfolio to Clorox's existing cleaning and household products. This transaction reflects a move to broaden Clorox's exposure beyond traditional household categories. Clorox enters this deal with its shares at $96.44, after a 27.3% decline over the past year and a 38.1% decline over the past five years. The acquisition of GOJO and Purell gives the...

St. Joe (JOE) opened 2026 with Q1 revenue of US$99 million and basic EPS of US$0.24, compared with Q1 2025 revenue of US$94 million and EPS of US$0.30. Trailing twelve month EPS stood at US$1.94 on revenue of US$518 million. Over that same twelve month stretch, net income reached US$112 million, giving investors a fuller view of how quarterly earnings feed into the broader profit picture. With a net margin of 21.6% over the last year, the latest numbers keep the spotlight firmly on how...

If you are wondering whether Meritage Homes at around US$67.34 is a bargain or just fairly priced, this breakdown will help you frame what the current share price might actually be offering you. The stock has recently been choppy, with a 3.7% decline over the last 7 days, an 8.9% gain over the past 30 days, and returns of 1.7% year to date and 3.2% over the last year. Recent coverage has focused on how Meritage Homes fits into the broader US homebuilding sector, with attention on its ability...

If you are wondering whether Centessa Pharmaceuticals at around US$39.42 is still offering value after its surge, you are asking the right question for this stock. The share price has delivered a 66.4% return year to date and 192.0% over the last year, with the 3 year return described as very large, even though the last 30 days have seen a small 0.8% decline and the last week has been flat at 0.0%. Recent coverage has focused on Centessa Pharmaceuticals as a higher growth biotech name, and...

XP Inc. (NasdaqGS:XP) released its audited 2025 annual results, giving investors a detailed view of the company’s most recent financial year. The company announced a new cash dividend, signaling a direct return of capital to shareholders. XP also launched a fresh share repurchase program and reported significant ownership positions held by institutional investors. XP operates as a financial services platform, connecting retail and institutional clients to investment products and advisory...

Shareholders of Generac Holdings Inc. ( NYSE:GNRC ) will be pleased this week, given that the stock price is up 19% to...

This article considers whether NIQ Global Intelligence, at around US$10.93, offers value or simply appears cheap on the surface by examining what the current price might really imply. The share price has eased back recently, with a 7‑day return of a 2.6% decline, a 30‑day return of a 3.9% decline, and a year‑to‑date return of a 30.7% decline. Recent coverage has focused on the stock's weaker near‑term returns and what they might signal about investor expectations, which helps explain why...

Investors may be wondering if Celanese is still attractively priced after its recent run, or if most of the value story is already reflected in the share price. The stock last closed at US$67.76, with returns of 3.9% over the past week, 3.0% over the past month, 60.7% year to date, and 49.6% over the past year, set against longer term returns of negative 30.6% over three years and negative 56.5% over five years. Recent coverage has focused on Celanese's position in the chemicals sector and...

In the last week, the market has stayed flat, but over the past 12 months, it has risen by 29%, with earnings forecasted to grow annually by 16%. While penny stocks might seem like a term from a bygone era, they still hold significant potential for investors looking to explore smaller or newer companies that boast strong financials. This article highlights three such penny stocks that could offer both affordability and growth opportunities in today's market landscape.

Wondering if Coastal Financial at US$75.62 is offering good value right now, or if the recent price action suggests you should be more cautious. The stock has seen a 9.9% decline over the last 7 days and is down 33.3% year to date, despite a 123.6% return over 3 years and 158.9% over 5 years. Recent news coverage has focused on Coastal Financial as a regional bank stock that has already delivered strong multi year returns, which can prompt questions about how much upside is left. At the same...

Unum Group (NYSE:UNM) has appointed Steve Jones as the new president of its Colonial Life business. Jones succeeds Tim Arnold, who is retiring after a 41 year career with the organization. The leadership change comes as Colonial Life reports record earnings and strong business performance. For investors watching NYSE:UNM, this move comes with the stock at $80.38, with a 3 year return of 102.6% and a 5 year return of 212.6%. Recent share performance has also been firm, with the stock up 3.4%...

The Bank of N.T. Butterfield & Son Limited ( NYSE:NTB ) just released its latest quarterly results and things are...

Hayward Holdings, Inc. ( NYSE:HAYW ) defied analyst predictions to release its quarterly results, which were ahead of...

Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) just released its first-quarter report and things are looking bullish. The...

This article examines whether Sensata Technologies Holding, at around US$41.64, is priced for further upside or already reflects most of its story, focusing squarely on what the numbers indicate about value. The stock has returned 18.2% over the last 30 days and 97.8% over the past year. The year-to-date return is 19.3%, while the 5-year return is a 24.0% decline. Recent coverage has highlighted the stock's strong 1-year return of 97.8% and contrasted that with its weaker 5-year record. This...

Hadron Energy and ConverDyn have agreed to use Solstice Advanced Materials’ uranium conversion facility to support the first commercial rollout of a new domestic Halo Micro-Modular Reactor. The partnership centers on creating a U.S. based fuel supply chain for advanced nuclear technologies. Solstice Advanced Materials, listed as NasdaqGS:SOLS, sits at the core of this arrangement as the conversion partner within the nuclear fuel cycle. For investors tracking the U.S. nuclear fuel...

Last week saw the newest third-quarter earnings release from Carpenter Technology Corporation ( NYSE:CRS ), an...

Investors in CTS Corporation ( NYSE:CTS ) had a good week, as its shares rose 2.8% to close at US$57.10 following the...